Cynomolgus Monkey CXCL7 ELISA

Catalog Number:
DIY1995Y
Application:
ELISA
100% Homology:
Macaca fascicularis (crab-eating macaque), Macaca mulatta (Rhesus monkey)

Components

UsageQuantityComponentSize
Detection Antibody50 µgKPB1994Y-050
Standard5 µgRP1776Y-005
Capture Antibody100 µgKP1993Y-1001 Pack (<= 10 Plates)
Capture Antibody100 µg X 2KP1993Y-1001 Pack (<= 20 Plates)
  • The Cynomolgus Monkey CXCL7 (C-X-C motif chemokine ligand 7, also known as NAP-2/PPBP) ELISA is designed for the quantitative measurement of CXCL7 in cell culture supernatants from Cynomolgus monkeys (Macaca fascicularis) and can also be used to measure CXCL7 in additional biological sample types reported in the literature, including serum, plasma, and platelet-rich plasma, with minor protocol modifications recommended to optimize performance across different matrices. The CXCL7 protein sequence in Cynomolgus monkey is identical to that of Rhesus monkey (Macaca mulatta), allowing this assay to be used for accurate detection in both species. CXCL7 is a platelet-derived CXC chemokine released upon platelet activation and is involved in neutrophil chemotaxis, activation, and adhesion, functioning primarily through CXCR2 to promote recruitment of neutrophils to sites of vascular injury or inflammation. In healthy non-human primates, circulating CXCL7 levels are influenced by platelet activation status and are typically low in resting plasma but may increase significantly following platelet activation, inflammatory stimulation, vascular injury, immune challenge, or toxicologic insult. In Cynomolgus and Rhesus monkey models, CXCL7 serves as an important biomarker of platelet activation, thromboinflammatory responses, neutrophil trafficking, and vascular inflammation, making it particularly relevant in cardiovascular research, preclinical safety studies, inflammatory disease models, and evaluation of biologic therapeutics. The ELISA kit contains a capture antibody, detection antibody, and recombinant Cynomolgus monkey CXCL7 protein standard validated for use together in an ELISA format; kit components are not supplied in matched quantities and may be purchased separately. This product is for research use only, not for use in diagnostic or therapeutic procedures, and is manufactured in the USA.
Storage Conditions2°C to 8°C or -20°C
Country Of OriginUSA
Cynomolgus Monkey (Macaca fascicularis) CXCL7 (C-X-C motif chemokine ligand 7), also known as NAP-2 (neutrophil-activating peptide 2) or PPBP (pro-platelet basic protein), is a platelet-derived chemokine belonging to the ELR⁺ CXC chemokine family, which includes CXCL1, CXCL2, CXCL3, and CXCL5 that regulate neutrophil recruitment during inflammatory responses. In cynomolgus monkeys, CXCL7 is produced primarily by platelets and megakaryocytes and is released during platelet activation triggered by vascular injury, inflammation, or infection. CXCL7 signals mainly through the chemokine receptor CXCR2, expressed on neutrophils and other innate immune cells, promoting neutrophil chemotaxis, activation, and migration to sites of tissue damage or inflammation. In this species, CXCL7 contributes to the coordination of coagulation and immune responses, influencing platelet–leukocyte interactions, vascular inflammation, and tissue repair. Because cynomolgus monkeys share close genetic, physiological, and immunological similarity with humans, they are widely used as preclinical animal models for cardiovascular and inflammatory diseases. In particular, CXCL7 has been examined in nonhuman primate models of thrombosis and atherosclerosis, where platelet-derived chemokines regulate leukocyte recruitment to vascular endothelium and progression of vascular inflammation, helping researchers evaluate antithrombotic therapies and mechanisms of platelet-mediated immune signaling relevant to human disease.
  • Chemokine

Please choose a size to see price


Reagents for Animal Model and Animal Health Research

Kingfisher Biotech, Inc.
1000 Westgate Drive
Suite 123
Saint Paul, MN 55114

Phone: 651-646-0089
Fax: 651-646-0095

Animal Antibodies

Newsletter

"